Aprea AB – Product Pipeline Review – 2012

Publication date: September 2012
Report size: 26 pages

Keywords : Pharmaceutical, pharmaceuticals report

Aprea AB – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Aprea AB - Product Pipeline Review - 2012” provides data on the Aprea AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and info...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Aprea AB – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Aprea AB - Product Pipeline Review - 2012” provides data on the Aprea AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aprea AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Aprea AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aprea AB - Brief Aprea AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aprea AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aprea AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aprea AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aprea AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aprea AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aprea AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aprea AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aprea AB and identify potential opportunities in those areas.

Pharmaceutical Industry in Sweden

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Aprea AB Snapshot 4
Aprea AB Overview 4
Key Information 4
Key Facts 4
Aprea AB – Research and Development Overview 5
Key Therapeutic Areas 5
Aprea AB – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Aprea AB – Pipeline Products Glance 9
Aprea AB Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Aprea AB – Early Stage Pipeline Products 10
Discovery Products/Combination Treatment Modalities 10
Aprea AB – Drug Profiles 11
APR-246 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
RITA Program 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Wrap-53 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Aprea AB – Pipeline Analysis 14
Aprea AB – Pipeline Products by Therapeutic Class 14
Aprea AB – Pipeline Products by Route of Administration 15
Aprea AB – Pipeline Products By Mechanism of Action 16
Aprea AB – Recent Pipeline Updates 17
Aprea AB – Locations And Subsidiaries 18
Head Office 18
Aprea AB, Recent Developments 19
Aprea AB- Press Release 19
Dec 03, 2009: Aprea Presents Preclinical Data And Update From The Clinical PhaseI/IIa Cancer Study On APR-246 At The American Society of Hematology Annual Meeting 19
Nov 25, 2009: Aprea AB Receives Allowance Of A Key Patent In US And Europe 19
Sep 30, 2009: Aprea's Phase I Study With APR-246 Has Started To Include Patients From June 2009 20
Apr 08, 2009: The Swedish Medical Products Agency Approves Start Of clinical Phase I Trial Of Aprea’s First Candidate Drug, APR-246 20
Mar 06, 2009: Newly Discovered Gene Plays Vital Role In Cancer 21
Financial Deals Landscape 22
Aprea AB, Deals Summary 22
Aprea AB, Pharmaceuticals & Healthcare, Deal Details 23
Venture Financing 23
Aprea Secures $3.2 Million In Venture Financing 23
Aprea Secures $3.93 Million In Venture Financing 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables

Aprea AB, Key Information 4
Aprea AB, Key Facts 4
Aprea AB – Pipeline by Indication, 2012 6
Aprea AB – Pipeline by Stage of Development, 2012 7
Aprea AB – Monotherapy Products in Pipeline, 2012 8
Aprea AB – Phase I, 2012 9
Aprea AB – Discovery, 2012 10
Aprea AB – Pipeline By Therapeutic Class, 2012 14
Aprea AB – Pipeline By Route of Administration, 2012 15
Aprea AB – Pipeline Products By Mechanism of Action, 2012 16
Aprea AB – Recent Pipeline Updates, 2012 17
Aprea AB, Deals Summary 22
Aprea Secures $3.2 Million In Venture Financing 23
Aprea Secures $3.93 Million In Venture Financing 24

List of Figures

Aprea AB – Pipeline by Indication, 2012 6
Aprea AB – Pipeline by Stage of Development, 2012 7
Aprea AB – Monotherapy Products in Pipeline, 2012 8
Aprea AB – Pipeline By Therapeutic Class, 2012 14

Cancer in Sweden